Scarica l'app Stockscreener
6.07
2.25%
-0.14
Dopo l'orario di chiusura:
6.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$6.21
Aprire:
$6.18
Volume 24 ore:
3.29M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.87B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-17.85
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-2.41%
1M Prestazione:
-19.28%
6M Prestazione:
-39.18%
1 anno Prestazione:
-38.56%
Intervallo 1D:
$6.03
$6.195
Intervallo di 1 settimana:
$6.03
$6.38
Portata 52W:
$5.81
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.07 | 1.92B | 493.67M | -104.69M | -31.51M | -0.34 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News - GuruFocus
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewswire
Rare Disease Leader Amicus Therapeutics to Present Latest Updates at Major Healthcare Conferences - Stock Titan
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Voloridge Investment Management LLC - MarketBeat
Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Neo Ivy Capital Management Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Ameriprise Financial Inc. - Defense World
Pompe Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Teza Capital Management LLC Sells 68,066 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC - MarketBeat
Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Enzyme Replacement Therapy Market Set to Witness Significant - openPR.com
Janus Henderson Group PLC Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Fabry Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Prosight Management LP Buys Shares of 920,000 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by D. E. Shaw & Co. Inc. - MarketBeat
Enzyme Replacement Therapy Market Generated Opportunities, - openPR.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Cut by BNP Paribas Financial Markets - MarketBeat
Orbimed Advisors LLC Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Northern Trust Corp Has $31.76 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Hudson Bay Capital Management LP Buys 379,800 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Batten Disease Treatment Market Size, Outlook 2031 by Key - openPR.com
Parkman Healthcare Partners LLC Has $7.39 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Balyasny Asset Management L.P. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 13,983 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now? - Insider Monkey
Bayesian Capital Management LP Purchases 54,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Long Term Trading Analysis for (FOLD) - news.stocktradersdaily.com
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):